Mitsuhiro Furuta

Mitsuhiro Furuta

Auto-generated profile, based on publicly available information

Mitsuhiro Furuta

Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2018 in Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
NMNaoki Mizuno
Naoki Mizuno
YSYuya Seko
Yuya Seko
SKSeita Kataoka
Seita Kataoka
KOKeiichiroh Okuda
Keiichiroh Okuda
MFMitsuhiro Furuta
Mitsuhiro Furuta
YIYoshito Itoh
Yoshito Itoh

3 July 2018 in Digestive Diseases
Verified
Journal Article
Closed access
PDF file
MFMitsuhiro Furuta
Mitsuhiro Furuta
MMMichihisa Moriguchi
Michihisa Moriguchi
KOKeiichiro Okuda
Keiichiro Okuda
SKSeita Kataoka
Seita Kataoka
NMNaoki Mizuno
Naoki Mizuno
YIYoshito Itoh
Yoshito Itoh
Aim: In Japan, transcatheter arterial chemoembolization (TACE) refractoriness for hepatocellular carcinoma has been defined as an insufficient therapeutic effect after ≥2 procedures. Insufficient TACE for intrahepatic lesions is defined as the presence of > 50% viable lesions (ineffective) or an increase in their number (progressive). This study aimed to examine the possibility of earlier evaluation of TACE refractoriness. Methods: Patients who underwent TACE for hepatocellular carcinomas > 3 cm in size or with > 3 nodules at our hospital between 2010 and 2014 were analyzed. The cases assessed as TACE insufficient for the first time were divided into 2 groups: the “either” group, evaluated as either “ineffective” or “progressive,” and the “both” group, that is, both “ineffective” and “progressive.” Results: The study participants included 40 of 212 consecutive patients who underwent TACE, divided into the either (n = 23) and both (n = 17) groups. Seventeen of 23 (73.9%) patients in the either group and all 17 (100%) in the both group had TACE refractoriness (p = 0.0295). Conclusions: Patients with both “ineffective” and “progressive” lesions are extremely likely to be TACE ­refractory at a significantly higher frequency than are those with either condition. Thus, when both of these factors are observed, switching to other therapies should be considered.

14 August 2024 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
MFMitsuhiro Furuta
Mitsuhiro Furuta
KHKei Hayashi
Kei Hayashi
MWMamoru Watanabe
Mamoru Watanabe
THTakanori Hama
Takanori Hama
MOMisa Onishi
Misa Onishi
SMShin Maeda
Shin Maeda
The post-insertion clinical course of esophageal self-expandable metal stents (SEMS) in initially frail patients with esophageal carcinoma (EC) with dysphagia remains unclear. This study aimed to assess dysphagia improvement and evaluate prognosis in initially frail patients with advanced EC following SEMS insertion. We retrospectively reviewed EC patients with EC who underwent esophageal SEMS insertion at our institution between January 2014 and March 2023. Inclusion criteria comprised Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≥ 3 or ECOG PS 2 for individuals aged ≥ 75 years and recommendation for best supportive care by a multidisciplinary team. Forty-six patients met the inclusion criteria. Among them, 37 patients (80.4%) were ≥ 75 years old, and 21 patients (45.7%) exhibited ECOG PS 3 or 4. Dysphagia score (DS) ≥ 3 was observed in 27 patients (58.7%). All esophageal SEMS insertions were successfully completed. Post-procedure, there were two fatal cases of aspiration pneumonia and one perforation incident. DS improved to ≤ 1 in 25 patients (54.3%), with multivariate analysis indicating DS 3–4 and Glasgow Prognostic Score (GPS) 1–2 as negative predictive factors. The median overall survival was 4.1 months (95% confidence interval 1.8–6.5). Esophageal SEMS insertion effectively alleviated dysphagia in initially frail EC patients, yet prognosis remained poor, with occurrences of some fatal adverse events. Careful selection of candidates for esophageal SEMS insertions is crucial in this demographic, particularly considering the challenges in improving dysphagia for patients with DS 3–4 and GPS 1–2.

6 July 2026 in Cancer Medicine
Verified
Journal Article
Open access
NONozomu Ogura
Nozomu Ogura
MOMisa Ohnishi
Misa Ohnishi
RIRin Inamoto
Rin Inamoto
YKYosuke Kito
Yosuke Kito
KNKengo Nagashima
Kengo Nagashima
HSHirokazu Shoji
Hirokazu Shoji
Background: The CheckMate 649 trial showed the superiority of first‐line nivolumab plus chemotherapy (Nivo‐CT) over chemotherapy alone for advanced gastric or gastroesophageal junction (GEJ) cancer with a programmed cell death‐ligand 1 (PD‐L1) combined positive score (CPS) ≥ 5. However, few studies have investigated the correlation between PD‐L1 CPS and the efficacy of first‐line Nivo‐CT in the real‐world setting. Methods: This multicenter retrospective study included patients with unresectable advanced or recurrent gastric or GEJ cancer who were started on first‐line Nivo‐CT between December 2021 and December 2023 at any of four institutions in Japan. PD‐L1 CPS was classified into three groups (< 1, 1 to < 5, and ≥ 5) before the start of Nivo‐CT. Results: A total of 234 patients were included (median age 70 years; 64.5% male; 89.7% with gastric primary). PD‐L1 CPS was < 1 in 35 patients (15.0%), 1 to < 5 in 76 (32.5%), and ≥ 5 in 123 (52.5%). Median follow‐up was 14.0 months (range 2.3–30.3). Median overall survival was 18.7 (95% confidence interval [CI] 17.4–not reached), 23.4 (95% CI 17.7–not reached), and 18.3 months (95% CI 13.3–22.5), with objective response rates of 30.8%, 66.7%, and 61.3%. Multivariate analysis did not identify PD‐L1 CPS as a prognostic factor, whereas an Eastern Cooperative Oncology Group performance status ≥ 1, a GEJ primary, and two or more metastatic sites were associated with poor prognosis. Conclusions: The PD‐L1 CPS had no significant effect on prognosis in patients with unresectable advanced or recurrent gastric or GEJ cancer treated with first‐line Nivo‐CT.

28 March 2025 in Anticancer Research
Verified
Journal Article
Open access
PDF file
KFKyoko Furusawa
Kyoko Furusawa
MFMitsuhiro Furuta
Mitsuhiro Furuta
MOMisa Onishi
Misa Onishi
THTakanori Hama
Takanori Hama
SIShuntaro Ishikawa
Shuntaro Ishikawa
SMShin Maeda
Shin Maeda
Background/Aim: Based on the CheckMate 649 study, nivolumab plus chemotherapy is the first-line treatment for human epidermal growth factor receptor 2-negative advanced gastric cancer (AGC). 5-fluorouracil/leucovorin+oxaliplatin (FOLFOX) is often used for patients with AGC with severe peritoneal metastasis (PM) who cannot tolerate oral intake. Nivolumab monotherapy has shown efficacy against PM. However, the efficacy and safety of nivolumab plus FOLFOX (NIVO+FOLFOX) remain unclear. Patients and Methods: We retrospectively examined 15 patients with AGC with severe peritoneal metastasis who received NIVO+FOLFOX between January 2022 and December 2023 at our institution. Severe PM was defined as massive ascites and/or inadequate oral intake. Results: Patients had a median age of 68 years, with 73.3% being male. Eastern Cooperative Oncology Group Performance Status 2 was observed in 20% of patients. Massive ascites was present in 86.7%, and 26.7% had inadequate oral intake. Combined positive score ≥5 was observed in 60%, and no patient had microsatellite instability-high. Median progression-free survival was 4.2 months [95% confidence interval (CI)=0.62–10.6], and median overall survival was 4.5 months (95%CI=1.48–22.5). Despite poor overall prognosis, 20.0% achieved disease control beyond 1 year. Of 13 patients with massive ascites, 38.5% responded, and 30.7% achieved complete ascites resolution. Grade ≥3 immune-related adverse events included sialadenitis, myocarditis, and hepatitis (n=1 each). No treatment-related deaths occurred. Conclusion: NIVO+FOLFOX was feasible for patients with AGC with severe PM, providing potential for long-term survival and ascites reduction.

1 April 2026 in JCO Oncology Advances
Verified
Journal Article
Closed access
Koki NakanishiKoki Nakanishi
Koki Nakanishi
MFMitsuhiro Furuta
Mitsuhiro Furuta
TOTakashi Oshima
Takashi Oshima
DKDaisuke Kobayashi
Daisuke Kobayashi
TMToshifumi Murai
Toshifumi Murai
MKMitsuro Kanda
Mitsuro Kanda
PURPOSE: Trifluridine/tipiracil (FTD/TPI) plus ramucirumab may improve survival as a later-line therapy for advanced gastric cancer (GC); however, prospective evidence is limited. PATIENTS AND METHODS: We conducted a multicenter, prospective phase II trial of FTD/TPI plus ramucirumab in patients with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma who had received at least two previous systemic regimens for advanced disease, including a ramucirumab-containing regimen. Eligible patients had an Eastern Cooperative Oncology Group performance status of 0-2 and adequate organ function. Patients received oral FTD/TPI (35 mg/m 2 , days 1-5 and 8-12) and ramucirumab (8 mg/kg, days 1 and 15) every 28 days. The primary end point was time to treatment failure (TTF), and the secondary end points were progression-free survival (PFS), overall survival (OS), response, disease control rate (DCR), relative dose intensity (RDI), and safety. RESULTS: Between February 2022 and March 2024, 32 patients were enrolled (median age, 72.5 years; 53.1% male). The median TTF was 4.0 months (95% CI, 2.8 to 5.0), meeting the primary end point. Median PFS and OS were 4.8 (95% CI, 2.8 to 8.3) and 12.2 months (95% CI, 7.8 to 17.2), respectively. Among 26 patients with measurable disease, objective response rate was 11.5%, and DCR was 76.9%. Mean RDI was 78.6% for FTD/TPI and 93.1% for ramucirumab, supporting feasibility in this cohort. Grade ≥3 neutropenia occurred in 53.1% and febrile neutropenia in 9.4%. Frequent nonhematologic events were anorexia (68.8%) and fatigue (59.4%), mostly grade 1 to 2. A modified FTD/TPI schedule was introduced in 15 patients and maintained dose delivery while reducing neutropenia, with no febrile events. CONCLUSION: FTD/TPI plus ramucirumab met its primary end point and was feasible with manageable safety in heavily pretreated advanced GC. Given the single-arm design, the efficacy findings are hypothesis-generating and warrant confirmation in larger randomized trials.